|72.99||+0.9200||+1.28%||Vol 655.10K||1Y Perf -6.17%|
|Aug 12th, 2022 16:00 DELAYED|
|- -||-0.08 -0.11%|
|Target Price||79.60||Analyst Rating||Moderate Buy 2.25|
|Potential %||9.06||Finscreener Ranking||★★★+ 52.50|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★ 56.13|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 67.47|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||44.33||Earnings Rating||Neutral|
|Market Cap||18.22B||Earnings Date||27th Jul 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||0.69|
|EPS Growth Next 5 Years %||14.40|
|Avg. Weekly Volume||1.13M|
|Avg. Monthly Volume||1.52M|
|Avg. Quarterly Volume||1.73M|
Hologic Inc. (NASDAQ: HOLX) stock closed at 72.99 per share at the end of the most recent trading day (a 1.28% change compared to the prior day closing price) with a volume of 655.10K shares and market capitalization of 18.22B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 5814 people. Hologic Inc. CEO is Stephen P. Macmillan.
The one-year performance of Hologic Inc. stock is -6.17%, while year-to-date (YTD) performance is -4.66%. HOLX stock has a five-year performance of 91.07%. Its 52-week range is between 66.58 and 81.04, which gives HOLX stock a 52-week price range ratio of 44.33%
Hologic Inc. currently has a PE ratio of 12.20, a price-to-book (PB) ratio of 3.60, a price-to-sale (PS) ratio of 3.44, a price to cashflow ratio of 7.60, a PEG ratio of 2.32, a ROA of 17.84%, a ROC of 21.34% and a ROE of 35.90%. The company’s profit margin is 29.00%, its EBITDA margin is 45.70%, and its revenue ttm is $5.23 Billion , which makes it $20.93 revenue per share.
Of the last four earnings reports from Hologic Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.69 for the next earnings report. Hologic Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Hologic Inc. is Moderate Buy (2.25), with a target price of $79.6, which is +9.06% compared to the current price. The earnings rating for Hologic Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Hologic Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Hologic Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.58, ATR14 : 1.69, CCI20 : 127.85, Chaikin Money Flow : 0.26, MACD : 0.38, Money Flow Index : 52.56, ROC : 2.89, RSI : 45.94, STOCH (14,3) : 93.74, STOCH RSI : 1.00, UO : 51.95, Williams %R : -6.26), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Hologic Inc. in the last 12-months were: Benjamin J. Cohn (Option Excercise at a value of $434 798), Benjamin J. Cohn (Sold 15 644 shares of value $1 191 450 ), Jan Verstreken (Sold 6 500 shares of value $512 168 ), Sean S. Daugherty (Sold 2 179 shares of value $155 016 )
Fri, 29 Jul 2022 05:27 GMT Analysts Offer Insights on Healthcare Companies: Hologic (HOLX) and Myovant Sciences (MYOV)- TipRanks. All rights reserved.
Thu, 28 Jul 2022 09:55 GMT Hologic (HOLX) Gets a Hold Rating from Needham- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.